Will McKesson account for more than 15% of ADMA's revenue by Q4 2026?

Ramping a new specialty biologic distribution channel to 15% of revenue within roughly one year is ambitious. McKesson is the largest US pharma distributor and has the infrastructure, but ASCENIV is a high-cost specialty product that requires specific formulary placement, payer contracts, and physician relationship development. BioCare and CuraScript currently control 73% of revenue and likely have established relationships with ASCENIV-prescribing physicians. Switching distribution for an ongoing biologic therapy is not as simple as adding a new distributor. 15% of estimated Q4 2026 revenue (~$170M) = ~$25.5M through McKesson from a standing start. This is a significant ramp.

McKesson scale and existing specialty pharmacy network could accelerate the ramp beyond typical timelines. ADMA has strong incentive to diversify channels given the AR concentration risk. Management explicitly highlighted McKesson as a channel diversification strategy on earnings calls, suggesting active commercial effort. However, 15% is a specific and meaningful threshold. More realistic might be 5-10% by Q4 2026 with 15%+ achieved in 2027. The question also allows for McKesson revenue to not be separately disclosed, which would resolve NO. Specialty pharma distribution agreements often involve gradual ramp-up schedules.

Distribution channel transitions in specialty pharma are complex. Payer contracts may specify distribution channels. Physician prescribing patterns are sticky. New distributor onboarding involves formulary placement, specialty pharmacy network enrollment, co-pay assistance program setup, and patient hub services coordination. Even with aggressive management push, achieving 15% channel share in less than 12 months from agreement signing is at the upper end of industry experience. I lean toward 10% or less by Q4 2026, with 15% achievable in H1 2027.

The 15% threshold is a meaningful bar. McKesson has the infrastructure but specialty biologic distribution involves more than logistics. It requires formulary placement, specialty pharmacy relationships, and payer contract alignment. ADMA management clearly wants channel diversification and has commercial incentive to push McKesson adoption. But structural factors (existing BioCare/CuraScript relationships, payer contracts, physician prescribing inertia) create friction. I estimate 8-12% McKesson share by Q4 2026 as the base case, making 15% possible but below 50% probability.

Resolution depends partly on disclosure. If ADMA does not separately disclose McKesson revenue, the question resolves NO regardless of actual channel mix. Companies often do not disclose individual distributor revenue until the distributor becomes a top-3 customer. This resolution structure biases toward NO. Even if McKesson achieves 12% of revenue, ADMA might not disclose it separately until it exceeds BioCare/CuraScript in some metric. Low probability due to both execution challenge and disclosure uncertainty.

Management signaling is clear: McKesson is the answer to channel concentration. But signaling intent and achieving 15% channel share in less than a year are different things. ASCENIV new patient starts through McKesson channel could ramp, but existing patients on BioCare/CuraScript will not switch distributors easily. The growth in McKesson share would come primarily from new patient enrollment through McKesson-affiliated specialty pharmacies. At 51% ASCENIV growth, new patient starts are substantial, but only a fraction would route through McKesson in year one.

From zero to 15% in one year is ambitious for specialty biologic distribution. McKesson has scale but ASCENIV distribution is complex. BioCare/CuraScript relationships are entrenched. 15% is above realistic year-one expectations. Low probability.

Specialty pharma channel transitions take time. Payer contracts and physician prescribing patterns are sticky. 15% would require either aggressive patient switching or massive new enrollment through McKesson. Neither is likely in first year. Very low probability.

McKesson has scale but specialty biologic distribution ramp-up is inherently slow. Management wants diversification but 15% in year one exceeds typical new channel adoption. More realistic timeline is 15%+ in 2027. Low probability for Q4 2026.